It is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms. Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.
• Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia
• Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])
• Community-acquired pneumonia caused by Streptococcus pneumoniae (including multidrug resistant strains [MDRSP]), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).
• Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillinsusceptible and resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae.
LIZOLID has not been studied in the treatment of decubitus ulcers.
• Uncomplicated skin and skin structure infections caused by Staphylococcus aureus
(methicillin-susceptible only) or Streptococcus pyogenes.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of LIZOLID and other antibacterial drugs, LIZOLID should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.